RNA BIOCHEMISTRY IS ONE OF THE MOST PROMISING AREAS OF MEDICINAL INNOVATION
First Health Pharmaceuticals has a leading position in the field of advanced RNA biochemistry. We aim to further develop our portfolio of highly active patented RNA Helicase inhibiting lead compounds and bring revolutionary pharmaceuticals to the market that will offer new hope for patients suffering from some of the most challenging diseases of our time.
HIV RESERVOIR REDUCTION
First Health Pharma developed the first ever generation of Translation Inhibitor compounds effective against HAART resistant HIV strains and is investigating potential strategies to be applied in a HIV Shock & Kill approach.
The translation of RNA to proteins is fundamental for cell survival and replication, thus First Health Pharmaceuticals has set its RNA Research priorities on the development of RNA Helicase inhibiting lead compounds.
DDX3 RNA helicase has remarkable oncogenic properties. It is overexpressed in the malignant types of Breast and Lung cancer. Our DDX3 inhibitors can be considered apoptosis-inducing targeted antitumor agents.